Loading patent…
AssigneeChiron Corporation
InventorsDavid T. Hung, Brian H. Annex, Kevin P. Landolfo, W. Michael Kavanaugh
Estimating the term…
The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis. In another aspect, the present invention is directed to a method for treating a patient for coronary artery disease, comprising administering directly into the myocardium in an area of need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. In yet another aspect, the present invention is directed to a method for treating a patient for a myocardial infarction, comprising administering directly into the myocardium in an area in need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent.
A pharmaceutical composition comprising an effective amount of an angiogenic agent in a pharmaceutically acceptable carrier, said effective amount of angiogenic agent being in the range from about 5 ng to less than about 135,000 ng of said angiogenic agent.
A method for increasing vascular perfusion in the myocardium comprising injecting an area of the myocardium in need of an increase in perfusion with an effective amount of an angiogenic agent, said effective amount being within the range of about 5 ng to less than 135,000 ng of an angiogenic agent.
17 The method of claim 16, wherein said FGF is FGF-2 or an angiogenically active fragment or mutein thereof.
The method of claim 17, wherein said FGF-2 has the amino acid sequence of SEQ ID NO:
A method for increasing vascular density in the myocardium comprising injecting an area of the myocardium in need of an increase in perfusion with an effective amount of an angiogenic agent, said effective amount being within the range of about 5 ng to less than 135,000 ng of an angiogenic agent.
A method for inducing angiogenesis in a heart of a patient, comprising injecting an effective amount of an angiogenic agent directly into the myocardium of said patient in one or more areas in need of angiogenesis, said effective amount of angiogenic agent being from about 5 ng to less than 135,000 ng of said angiogenic agent.
A method for stimulating the production of FGF-2 and VEGF in human myocardial cells for up to three months, comprising injecting an effective amount of an angiogenic agent directly into the myocardium of said patient in one or more areas in need of angiogenesis, said effective amount of angiogenic agent being from about 5 ng to less than 135,000 ng of said angiogenic agent.
A method for treating a human patient for coronary artery disease, comprising injecting an effective amount of an angiogenic agent directly into the myocardium in one or more areas in need of treatment for said disease, said effective amount of angiogenic agent being from about 5 ng to less than 135,000 ng of said angiogenic agent.
The method claim 36, wherein said angiogenic agent is VEGF-A, VEGF-D FGF, or is an angiogenically active fragment or mutein thereof.
The method of claim 37, wherein said VEGF-A is human VEGF-A121, VEGF-A165, VEGF-A189, or VEGF-A206.
The method of claim 40, wherein said FGF-2 has amino acid sequence of SEQ ID NO:2, 5 or 6.
Dependencies are inferred from the claim text.